News | November 23, 2023
AstraZeneca Pharma India receives permission to Import formulations of new drug for sale
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
Subscribe To Our Newsletter & Stay Updated
